The endocannabinoid system and its therapeutic exploitation

The term 'endocannabinoid' — originally coined in the mid-1990s after the discovery of membrane receptors for the psychoactive principle in Cannabis, Δ9-tetrahydrocannabinol and their endogenous ligands — now indicates a whole signalling system that comprises cannabinoid receptors, endogenous ligands and enzymes for ligand biosynthesis and inactivation. This system seems to be involved in an ever-increasing number of pathological conditions. With novel products already being aimed at the pharmaceutical market little more than a decade since the discovery of cannabinoid receptors, the endocannabinoid system seems to hold even more promise for the future development of therapeutic drugs. We explore the conditions under which the potential of targeting the endocannabinoid system might be realized in the years to come.

[1]  L. Arendt-Nielsen,et al.  The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions , 2003, Pain.

[2]  C. Flachskamm,et al.  The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. , 2003, The Journal of clinical investigation.

[3]  R. Mechoulam,et al.  Discovery and characterization of endogenous cannabinoids. , 1999, Life sciences.

[4]  R. Palmiter,et al.  Leptin-regulated endocannabinoids are involved in maintaining food intake , 2001, Nature.

[5]  A. Yamashita,et al.  Transacylase-mediated and phosphodiesterase-mediated synthesis of N-arachidonoylethanolamine, an endogenous cannabinoid-receptor ligand, in rat brain microsomes. Comparison with synthesis from free arachidonic acid and ethanolamine. , 1996, European journal of biochemistry.

[6]  G. Ertl,et al.  Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. , 2001, Journal of the American College of Cardiology.

[7]  C. Hillard,et al.  Cellular accumulation of anandamide: consensus and controversy , 2003, British journal of pharmacology.

[8]  N. Darmani.  Δ9-Tetrahydrocannabinol and Synthetic Cannabinoids Prevent Emesis Produced by the Cannabinoid CB1 Receptor Antagonist/Inverse Agonist SR 141716A , 2001, Neuropsychopharmacology.

[9]  V. Di Marzo,et al.  Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. , 1996, The Biochemical journal.

[10]  Z. Vogel,et al.  2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  B. Cravatt,et al.  Increased Seizure Susceptibility and Proconvulsant Activity of Anandamide in Mice Lacking Fatty Acid Amide Hydrolase , 2003, The Journal of Neuroscience.

[12]  T. Freund,et al.  Brain monoglyceride lipase participating in endocannabinoid inactivation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[13]  L. Iversen,et al.  Cannabinoids: a real prospect for pain relief? , 2002, Current opinion in pharmacology.

[14]  C. Breivogel,et al.  Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide. , 2000, European journal of pharmacology.

[15]  D. Kendall,et al.  Cardiovascular effects of cannabinoids. , 2002, Pharmacology & therapeutics.

[16]  B. Martin,et al.  Cannabis: pharmacology and toxicology in animals and humans. , 1996, Addiction.

[17]  T. Bisogno,et al.  Possible endocannabinoid control of colorectal cancer growth. , 2003, Gastroenterology.

[18]  L. Petrocellis,et al.  An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. , 1998, European journal of pharmacology.

[19]  H. Iwamura,et al.  In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. , 2001, The Journal of pharmacology and experimental therapeutics.

[20]  R. Mechoulam,et al.  Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish , 1964 .

[21]  C. Newton,et al.  The cannabinoid system and immune modulation , 2003, Journal of leukocyte biology.

[22]  K. Mackie,et al.  Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. , 2001, Gastroenterology.

[23]  M. Karst,et al.  Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. , 2003, JAMA.

[24]  D. Walsh,et al.  Established and potential therapeutic applications of cannabinoids in oncology , 2003, Supportive Care in Cancer.

[25]  F. Bymaster,et al.  Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. , 2002, The Journal of pharmacology and experimental therapeutics.

[26]  T. Bisogno,et al.  Biosynthesis, Uptake, and Degradation of Anandamide and Palmitoylethanolamide in Leukocytes* , 1997, The Journal of Biological Chemistry.

[27]  V. Marzo,et al.  Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2‐arachidonoyl glycerol , 2002, British journal of pharmacology.

[28]  T. Bisogno,et al.  Endocannabinoids as physiological regulators of colonic propulsion in mice. , 2002, Gastroenterology.

[29]  J. Ramos,et al.  Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase. , 2003, Journal of medicinal chemistry.

[30]  J. Brotchie,et al.  Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study , 2001, Neurology.

[31]  S. Burstein.  Ajulemic acid (CT3): a potent analog of the acid metabolites of THC. , 2000, Current pharmaceutical design.

[32]  A. Fontana,et al.  Anandamide, an endogenous cannabinomimetic eicosanoid: 'killing two birds with one stone'. , 1995, Prostaglandins, leukotrienes, and essential fatty acids.

[33]  L. Petrocellis,et al.  Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action , 1998, Trends in Neurosciences.

[34]  M. Eder,et al.  CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity , 2003, Science.

[35]  T. Bonner,et al.  Structure of a cannabinoid receptor and functional expression of the cloned cDNA , 1990, Nature.

[36]  P. Calabresi,et al.  Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism , 2003, Journal of neurochemistry.

[37]  D. Fegley,et al.  Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[38]  A. Howlett,et al.  Determination and characterization of a cannabinoid receptor in rat brain. , 1988, Molecular pharmacology.

[39]  P. Casellas,et al.  SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. , 1998, The Journal of pharmacology and experimental therapeutics.

[40]  R. Pertwee.  Pharmacology of cannabinoid CB1 and CB2 receptors. , 1997, Pharmacology & therapeutics.

[41]  J. Brotchie,et al.  Striatal Cannabinoid CB1 Receptor mRNA Expression Is Decreased in the Reserpine-Treated Rat Model of Parkinson's Disease , 2001, Experimental Neurology.

[42]  B. Löwenberg,et al.  The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner. , 2004, Blood.

[43]  D. Cichewicz.  Synergistic interactions between cannabinoid and opioid analgesics. , 2004, Life sciences.

[44]  F. Berrendero,et al.  Changes in cannabinoid CB(1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. , 2001, Synapse.

[45]  M. Cascio,et al.  The endocannabinoid system and the molecular basis of paralytic ileus in mice , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[46]  R. Capasso,et al.  Cannabinoid CB1‐receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation , 2001, British journal of pharmacology.

[47]  Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD. , 2003, Drugs in R&D.

[48]  D. Piomelli,et al.  A second endogenous cannabinoid that modulates long-term potentiation , 1997, Nature.

[49]  D. Deutsch,et al.  Evidence against the presence of an anandamide transporter , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[50]  A. Sanyal,et al.  Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis , 2001, Nature Medicine.

[51]  D. Wade,et al.  A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms , 2003, Clinical rehabilitation.

[52]  C. Weinz,et al.  BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury. , 2006, CNS drug reviews.

[53]  H. Emrich,et al.  Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. , 2003, The Journal of clinical psychiatry.

[54]  Alberto Rábano,et al.  Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains , 2003, The Journal of Neuroscience.

[55]  T. Freund,et al.  Role of endogenous cannabinoids in synaptic signaling. , 2003, Physiological reviews.

[56]  J. Walker,et al.  Pain modulation by release of the endogenous cannabinoid anandamide. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[57]  T. Rubino,et al.  Is cannabinoid transmission involved in rewarding properties of drugs of abuse? , 2002, British journal of pharmacology.

[58]  W. Zieglgänsberger,et al.  The endogenous cannabinoid system controls extinction of aversive memories , 2002, Nature.

[59]  M. Elphick,et al.  Comparative analysis of fatty acid amide hydrolase and cb1 cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling , 2003, Neuroscience.

[60]  M. Kathmann,et al.  Modulation of transmitter release via presynaptic cannabinoid receptors. , 2001, Trends in pharmacological sciences.

[61]  M. L. de Ceballos,et al.  Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. , 2001, Cancer research.

[62]  P. C. Schmid,et al.  Metabolism of N-acylethanolamine phospholipids by a mammalian phosphodiesterase of the phospholipase D type. , 1983, The Journal of biological chemistry.

[63]  T. Bisogno,et al.  Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease , 2001, Neuroreport.

[64]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.

[65]  A. Howlett,et al.  Pharmacology of cannabinoid receptors. , 1995, Annual review of pharmacology and toxicology.

[66]  V. Di Marzo,et al.  Novel selective and metabolically stable inhibitors of anandamide cellular uptake. , 2003, Biochemical pharmacology.

[67]  R. Pertwee,et al.  Cannabinoids control spasticity and tremor in a multiple sclerosis model , 2000, Nature.

[68]  T. Bisogno,et al.  Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. , 1999, Biochemical and biophysical research communications.

[69]  R. Pertwee,et al.  Agonist‐inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630 , 1999, British journal of pharmacology.

[70]  R. Nicoll,et al.  Endocannabinoid Signaling in the Brain , 2002, Science.

[71]  K. Jin,et al.  Increased Severity of Stroke in CB1 Cannabinoid Receptor Knock-Out Mice , 2002, The Journal of Neuroscience.

[72]  Z. Vogel,et al.  Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. , 1995, Biochemical pharmacology.

[73]  N. Knoller,et al.  Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. , 2002, Critical care medicine.

[74]  D. Piomelli,et al.  Occurrence and Biosynthesis of Endogenous Cannabinoid Precursor,N-Arachidonoyl Phosphatidylethanolamine, in Rat Brain , 1997, The Journal of Neuroscience.

[75]  R. Roberts,et al.  Differential G protein-coupled cannabinoid receptor signaling by anandamide directs blastocyst activation for implantation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[76]  U. Hellman,et al.  cDNA Cloning, Tissue Distribution, and Identification of the Catalytic Triad of Monoglyceride Lipase , 1997, The Journal of Biological Chemistry.

[77]  R. Capasso,et al.  An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. , 2003, Gastroenterology.

[78]  P. Soubrié,et al.  SR141716A, a potent and selective antagonist of the brain cannabinoid receptor , 1994, FEBS letters.

[79]  David M. Lovinger,et al.  It could be habit forming: drugs of abuse and striatal synaptic plasticity , 2003, Trends in Neurosciences.

[80]  P. Soubrié,et al.  Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.

[81]  F. Walsh,et al.  The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response , 2003, The Journal of cell biology.

[82]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[83]  S. Schwab,et al.  Release of Fatty Acid Amides in a Patient With Hemispheric Stroke: A Microdialysis Study , 2002, Stroke.

[84]  A. Izzo,et al.  Cannabinoids for gastrointestinal diseases: potential therapeutic applications , 2003, Expert opinion on investigational drugs.

[85]  S. Ben-Shabat,et al.  An endogenous cannabinoid (2-AG) is neuroprotective after brain injury , 2001, Nature.

[86]  L. Petrocellis,et al.  Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. , 1999, European journal of biochemistry.

[87]  P. Soubrié,et al.  The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. , 2003, Molecular pharmacology.

[88]  V. Marzo,et al.  A new strategy to block tumor growth by inhibiting endocannabinoid inactivation , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[89]  A. Finazzi-Agro’,et al.  Low fatty acid amide hydrolase and high anandamide levels are associated with failure to achieve an ongoing pregnancy after IVF and embryo transfer. , 2002, Molecular human reproduction.

[90]  F. Berrendero,et al.  The endogenous cannabinoid system and brain development , 2000, Trends in Neurosciences.

[91]  D. Lambert,et al.  Lack of analgesic efficacy of oral δ-9-tetrahydrocannabinol in postoperative pain , 2003, Pain.

[92]  Stephen P. Mayfield,et al.  Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides , 1996, Nature.

[93]  Cristina Blázquez,et al.  Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. , 2003, The Journal of clinical investigation.

[94]  L. Petrocellis,et al.  Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. , 1998, Biochemical and biophysical research communications.

[95]  J. Brotchie,et al.  Randomised, double‐blind, placebo‐controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia , 2002, Movement disorders : official journal of the Movement Disorder Society.

[96]  M. Feldmann,et al.  A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. , 2004, Arthritis and rheumatism.

[97]  B. Cravatt,et al.  Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. , 2003, Current opinion in chemical biology.

[98]  A. Finazzi-Agro’,et al.  Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage , 2000, The Lancet.

[99]  P. Soubrié,et al.  CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity , 2004, International Journal of Obesity.

[100]  W. Campbell,et al.  Accumulation of N‐Arachidonoylethanolamine (Anandamide) into Cerebellar Granule Cells Occurs via Facilitated Diffusion , 1997, Journal of neurochemistry.

[101]  Gareth Williams,et al.  Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain , 2003, The Journal of cell biology.

[102]  B. Szabo,et al.  Analysis of the respiratory effects of cannabinoids in rats , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.

[103]  L. Wold,et al.  Anandamide and other N-acylethanolamines in human tumors , 2002, Lipids.

[104]  G. Portella,et al.  Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[105]  L. Petrocellis,et al.  The endocannabinoid system: a general view and latest additions , 2004, British journal of pharmacology.

[106]  D. Piomelli.  The molecular logic of endocannabinoid signalling , 2003, Nature Reviews Neuroscience.

[107]  Dale L Boger,et al.  Discovering potent and selective reversible inhibitors of enzymes in complex proteomes , 2003, Nature Biotechnology.

[108]  M. Glass,et al.  CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.

[109]  J. Zajicek,et al.  Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis ( CAMS study ) : multicentre randomised placebo-controlled trial , 2022 .

[110]  Michael T. Fisher,et al.  Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. , 2002, Blood.

[111]  D. Piomelli,et al.  Functional role of high-affinity anandamide transport, as revealed by selective inhibition. , 1997, Science.

[112]  P. Castillo,et al.  Heterosynaptic LTD of Hippocampal GABAergic Synapses A Novel Role of Endocannabinoids in Regulating Excitability , 2003, Neuron.

[113]  Pierangelo Geppetti,et al.  An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[114]  R. Kaiko,et al.  Oral morphine and respiratory function amongst hospice inpatients with advanced cancer , 2003, Supportive Care in Cancer.

[115]  M. Glass,et al.  Cannabis, cannabinoids and reproduction. , 2004, Prostaglandins, leukotrienes, and essential fatty acids.

[116]  F. Berrendero,et al.  Changes in cannabinoid CB1 receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis , 2001, Synapse.

[117]  B. Lutz,et al.  Further evidence for the existence of a specific process for the membrane transport of anandamide. , 2004, The Biochemical journal.

[118]  M. Vitale,et al.  Control by the endogenous cannabinoid system of ras oncogene‐dependent tumor growth , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[119]  T. Wenger,et al.  The role of endocannabinoids in the hypothalamic regulation of visceral function. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.

[120]  N. Ueda,et al.  Molecular Characterization of a Phospholipase D Generating Anandamide and Its Congeners* , 2004, Journal of Biological Chemistry.

[121]  B. Cravatt,et al.  Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia , 2004, Pain.

[122]  L. Petrocellis,et al.  The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[123]  M. Cortés,et al.  Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation , 2000, Nature Medicine.

[124]  Y. Kloog,et al.  Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[125]  T. Bisogno,et al.  Anandamide receptors. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.

[126]  Hui Li,et al.  Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid. , 2003, Molecular pharmacology.

[127]  H. Robertson,et al.  Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington’s disease mice , 2000, Neuroscience.

[128]  R. Mechoulam,et al.  HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[129]  L. Petrocellis,et al.  Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. , 1997, The Biochemical journal.

[130]  S. Gaetani,et al.  Modulation of anxiety through blockade of anandamide hydrolysis , 2003, Nature Medicine.

[131]  D. Deutsch,et al.  Cannabinoid properties of methylfluorophosphonate analogs. , 2000, The Journal of pharmacology and experimental therapeutics.

[132]  D. Cockayne,et al.  Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[133]  L. Petrocellis,et al.  Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor "hybrid" ligands. , 2001, Biochemical and biophysical research communications.

[134]  A. Yamashita,et al.  2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. , 1995, Biochemical and biophysical research communications.

[135]  I. Galve-Roperh,et al.  Cannabinoids and cell fate. , 2002, Pharmacology & therapeutics.

[136]  J. Liddle,et al.  Paradoxical Pharmacological Effects of Deoxy-Tetrahydrocannabinol Analogs Lacking High CB1 Receptor Affinity , 2002, Pharmacology.

[137]  B. Cravatt,et al.  A missense mutation in human fatty acid amide hydrolase associated with problem drug use , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[138]  B. Cravatt,et al.  The endogenous cannabinoid system protects against colonic inflammation. , 2004, The Journal of clinical investigation.

[139]  E. Ellis,et al.  Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock , 1997, Nature.

[140]  B. Cravatt,et al.  Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[141]  Dawn Carroll,et al.  Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review , 2001, BMJ : British Medical Journal.

[142]  F. Drago,et al.  Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade. , 2003, European journal of pharmacology.

[143]  J. Brotchie,et al.  Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[144]  A. Makriyannis,et al.  Endocannabinoids control spasticity in a multiple sclerosis model , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[145]  I. Grant,et al.  Non-acute (residual) neurocognitive effects of cannabis use: A meta-analytic study , 2003, Journal of the International Neuropsychological Society.

[146]  F. Mauler,et al.  3-[2-Cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): A Novel Cannabinoid CB1/CB2 Receptor Partial Agonist with Antihyperalgesic and Antiallodynic Effects , 2004, Journal of Pharmacology and Experimental Therapeutics.

[147]  R. Pertwee,et al.  O‐1057, a potent water‐soluble cannabinoid receptor agonist with antinociceptive properties , 2000, British journal of pharmacology.

[148]  J. W. Brooks,et al.  Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors. , 2002, European journal of pharmacology.

[149]  R. Faull,et al.  Loss of cannabinoid receptors in the substantia nigra in huntington's disease , 1993, Neuroscience.

[150]  Raymond C Stevens,et al.  Structural Adaptations in a Membrane Enzyme That Terminates Endocannabinoid Signaling , 2002, Science.

[151]  G. Kunos,et al.  Platelet‐ and macrophage‐derived endogenous cannabinoids are involved in endotoxin‐induced hypotension , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[152]  D. Ponde,et al.  Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide , 2001, British journal of pharmacology.

[153]  J. Schwartz,et al.  Formation and inactivation of endogenous cannabinoid anandamide in central neurons , 1994, Nature.

[154]  R. Mechoulam,et al.  Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. , 2002, Chemistry and physics of lipids.

[155]  G. Gessa,et al.  The synthetic cannabinoid WIN55212‐2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies , 2001, The European journal of neuroscience.